RNS Number : 0840H
ValiRx PLC
07 October 2024

ValiRx plc

("**ValiRx**" or the "**Company**")

Inaphaea Co-Marketing Agreement

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").

Inaphaea is pleased to confirm the execution of a co-marketing agreement ("Agreement") with the Italian biobanking service provider BioRep S.r.l ("BioRep"), a Sapio Group company, to provide Inaphaea's high throughput drug screening services and Patient Derived Cells ("PDC") to BioRep's network of clients. BioRep will provide backup samples storage and logistic services, in addition to molecular biology services into mainland Europe.

Inaphaea and BioRep will be entitled to a percentage of service or sales royalties on relevant contracts introduced by the respective party. Both companies have also agreed to co-market their respective services.

Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, commented "*This deal with BioRep expands our reach into Europe whilst providing backup storage and disaster management solutions.*"

Mark Eccleston, CEO of ValiRx, commented "*BioRep is an excellent partner as we look to offer our PDC product line into European markets. Their expertise in sample management, characterisation capabilities and access to a broad client base as well as logistics are a great fit for Inaphaea.*"

Michele Piovella, General Manager at BioRep, commented "*BioRep are constantly on the look out for new partners with innovative offerings and the Inaphaea Biobank addresses an unmet need for BioRep to be able to provide its current and future clients with oncology research samples and the relevant PDCs in addition to the well-established storage service. We look forward to a productive partnership and will explore additional areas to work together as we go forward.*"

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

*** ENDS ***

For more information, please contact:

ValiRx plc Dr Mark Eccleston, CEO	**Tel: +44 (0) 115 784 0026** **www.valirx.com** info@valirx.com
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director	**+44 (0) 115 787 0206** www.vformation.biz lucy@vformation.biz sue@vformation.biz
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Ludovico Lazzaretti	**Tel: +44 (0) 20 7213 0880**
Shard Capital Partners LLP (Sole Broker) Damon Heath	**Tel: +44 (0) 20 7186 9000**
BioRep srl **Daniela Sica (BU Biotech CCO)**	**Tel: +39 335 665 6824**
Sapio Group **Valentina Semeraro (Head of Media Relations)**	**Tel: +39 039 839 8242**

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

About BioRep

BioRep is a Sapio Group company established in Milan in 2003, as the first private Biological Resource Centre in Italy able to provide third parties services for biological material preservation to public and private research institutions, biotech and pharmaceutical companies, with the highest levels of quality and safety.

The main facility, embedded into the Biotechnology Department (DIBIT2) of San Raffaele Hospital, one of the largest Science Parks in Europe, has reached a total storage capacity of more than 9 million samples. The company strengthened its position as a reference player for public, private, national and international research centres, and focused its activities on the collection, the shipment, the processing, the storage and the distribution of biological samples.

This network of services is a key support for all the genetic, neurodegenerative, tumour and rare diseases research studies.

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRUNABRSUURRAA